Aurelie De Bruycker
Overview
Explore the profile of Aurelie De Bruycker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
622
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrews J, Andrews J, Kim Y, Horjeti E, Arafa A, Gunn H, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39820657
Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong ADT-free survival or progression-free survival (PFS) in patients with metachronous oligometastatic prostate cancer (omCSPC)...
2.
De Bruycker A, Schneiders F, Gulstene S, Moghanaki D, Louie A, Palma D, et al.
Lung Cancer
. 2024 Jun;
193:107848.
PMID: 38908164
Stereotactic ablative radiotherapy (SABR) is increasingly used for the treatment of early-stage non-small cell lung cancer (ES-NSCLC) and for pulmonary metastases. In patients with ES-NSCLC, SABR is highly successful with...
3.
De Bruycker A, De Neve W, Daisne J, Vercauteren T, De Gersem W, Olteanu L, et al.
Int J Radiat Oncol Biol Phys
. 2024 Feb;
120(2):516-527.
PMID: 38387811
Purpose: Local recurrence remains the main cause of death in stage III-IV nonmetastatic head and neck cancer (HNC), with relapse-prone regions within high F-fluorodeoxyglucose positron emission tomography (F-FDG-PET)-signal gross tumor...
4.
Danckaert W, Spaas M, Sundahl N, De Bruycker A, Fonteyne V, De Paepe E, et al.
Radiother Oncol
. 2023 Oct;
189:109950.
PMID: 37827280
Background: Prostate cancer patients treated with radiotherapy are susceptible to acute gastrointestinal (GI) toxicity due to substantial overlap of the intestines with the radiation volume. Due to their intimate relationship...
5.
Deek M, Van der Eecken K, Sutera P, Deek R, Fonteyne V, Mendes A, et al.
J Clin Oncol
. 2022 Aug;
40(29):3377-3382.
PMID: 36001857
JCO The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes...
6.
De Bruycker A, Tran P, Achtman A, Ost P
World J Urol
. 2020 Jan;
39(2):317-326.
PMID: 31955223
Purpose: Thanks to the introduction of more sensitive/specific imaging and minimally invasive treatment techniques, the oligometastatic state in prostate cancer (PCa) has attracted the interest of the uro-oncological community. We...
7.
De Bleser E, Willems R, Decaestecker K, Annemans L, De Bruycker A, Fonteyne V, et al.
Cancers (Basel)
. 2020 Jan;
12(1).
PMID: 31947974
The optimal management of patients with oligorecurrent prostate cancer (PCa) is unknown. There is growing interest in metastasis-directed therapy (MDT) for this population. The objective was to assess cost-utility from...
8.
De Bruycker A, Fonteyne V, Ost P
Eur Urol
. 2019 Jul;
76(5):e147-e148.
PMID: 31300235
No abstract available.
9.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al.
World J Urol
. 2018 Dec;
37(12):2557-2564.
PMID: 30578441
Purpose: Patients with oligometastatic prostate cancer (PC) may benefit from metastasis-directed therapy (MDT), delaying disease progression and the start of palliative systemic treatment. However, a significant proportion of oligometastatic PC...
10.
De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, et al.
Eur Urol
. 2018 Dec;
75(5):826-833.
PMID: 30503072
Background: Patients with biochemical recurrence following primary prostate cancer (PCa) treatment often experience relapse in the lymph nodes (LNs). Both salvage LN dissection (sLND) and elective nodal radiotherapy (ENRT) are...